Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [41] Association of CYP2D6 genotype predicted phenotypes with oxycodone requirements and side effects in children undergoing surgery
    Merchant, Soroush
    Prows, Cynthia A.
    Yang, Fang
    Ding, Lili
    MacDonald, Jacob
    Zhang, Xue
    Sadhasivam, Senthilkumar
    Garcia, Victor
    Sturm, Peter
    Chidambaran, Vidya
    ANNALS OF TRANSLATIONAL MEDICINE, 2022,
  • [42] A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine
    Jornil, J.
    Nielsen, T. S.
    Rosendal, I.
    Ahlner, J.
    Zackrisson, A. L.
    Boel, L. W. T.
    Brock, B.
    FORENSIC SCIENCE INTERNATIONAL, 2013, 226 (1-3) : E26 - E31
  • [43] Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine
    Chua, Eng Wee
    Foulds, James
    Miller, Allison L.
    Kennedy, Martin A.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (09) : 494 - 497
  • [44] Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
    Grzegorzewski, Jan
    Brandhorst, Janosch
    Koenig, Matthias
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6
    Lee, Joomi
    Yoo, Hee-Doo
    Bae, Jung-Woo
    Lee, Sooyeun
    Shin, Kwang-Hee
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1751 - 1761
  • [46] Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu, Adela
    Colle, Romain
    Gressier, Florence
    El Asmar, Khalil
    Becquemont, Laurent
    Corruble, Emmanuelle
    Verstuyft, Celine
    PHARMACOGENOMICS, 2017, 18 (07) : 639 - 650
  • [47] Effect of Garden Cress Seeds Powder and Its Alcoholic Extract on the Metabolic Activity of CYP2D6 and CYP3A4
    Al-Jenoobi, Fahad I.
    Al-Thukair, Areej A.
    Alam, Mohd Aftab
    Abbas, Fawkeya A.
    Al-Mohizea, Abdullah M.
    Alkharfy, Khalid M.
    Al-Suwayeh, Saleh A.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [48] Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry
    Berm, E.
    Kok, R.
    Hak, E.
    Wilffert, B.
    PHARMACOPSYCHIATRY, 2016, 49 (05) : 186 - 190
  • [49] Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
    Dickschen, Kristin
    Willmann, Stefan
    Thelen, Kirstin
    Lippert, Joerg
    Hempel, Georg
    Eissing, Thomas
    FRONTIERS IN PHARMACOLOGY, 2012, 3
  • [50] Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine A Pragmatic Randomized Controlled Trial (CYSCE Trial)
    van der Schans, Jurjen
    Hak, Eelko
    Postma, Maarten
    Breuning, Laura
    Brouwers, Jacobus R. B. J.
    Ditters, Kaspar
    Jansen, Paul A. F.
    Kok, Rob M.
    Maring, Jan G.
    van Marum, Rob
    Mulder, Hans
    Nanninga, Jaap
    Voshaar, Richard C. Oude
    Risselada, Arne J.
    Vleugel, Liesbeth
    Stek, Max
    van Schaik, Ron H. N.
    Berm, Elizabeth J. J.
    Wilffert, Bob
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (06) : 583 - 590
12345